PLYMOUTH MEETING, Pa., April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May:
The Citizens JMP Life Sciences Conference
Date: Tuesday, May 14, 2024
Time: 11:30 AM ET
Presenter: Dr. Jacqueline Shea, President & CEO
Format: Fireside Chat
RBC Capital Markets 2024 Global Healthcare Conference
Date: Wednesday, May 15, 2024
Time: 10:00 AM ET
Presenter: Dr. Jacqueline Shea, President & CEO
Format: Fireside Chat
H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Date: Monday, May 20, 2024
Time: 12:30 PM ET
Presenter: Dr. Jacqueline Shea, President & CEO
Format: Fireside Chat
During the conferences, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.
Webcasts of the fireside chats will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. Replays of the webcasts will be available for 90 days after the date of the presentation.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson (267) 429-8567 This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors: Thomas Hong (267) 440-4298 This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.59 |
Daily Change: | -0.06 -2.15 |
Daily Volume: | 689,419 |
Market Cap: | US$137.790M |
August 26, 2025 August 11, 2025 July 07, 2025 July 02, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load